Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups
- 24 March 2016
- journal article
- clinical trial
- Published by American Society of Hematology in Blood
- Vol. 127 (12), 1551-1558
- https://doi.org/10.1182/blood-2015-07-657403
Abstract
Key Points High-dose daunorubicin benefits AML patients with favorable and intermediate cytogenetics and with FLT3-ITD, NPM1, and DNMT3A mutations. High-dose daunorubicin is required for the favorable impact of the NPM1 mutation in AML.Keywords
This publication has 36 references indexed in Scilit:
- Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid LeukemiaNew England Journal of Medicine, 2013
- Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid LeukemiaNew England Journal of Medicine, 2012
- Autologous transplantation gives encouraging results for young adults with favorable-risk acute myeloid leukemia, but is not improved with gemtuzumab ozogamicinBlood, 2011
- Anthracycline Dose Intensification in Acute Myeloid LeukemiaNew England Journal of Medicine, 2009
- High-Dose Daunorubicin in Older Patients with Acute Myeloid LeukemiaNew England Journal of Medicine, 2009
- Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutationsBlood, 2005
- Dose Escalation Studies of Cytarabine, Daunorubicin, and Etoposide With and Without Multidrug Resistance Modulation With PSC-833 in Untreated Adults With Acute Myeloid Leukemia Younger Than 60 Years: Final Induction Results of Cancer and Leukemia Group B Study 9621Journal of Clinical Oncology, 2004
- Effect of Induction Cytarabine Dose Intensity on Long-Term Survival in Acute Myelogenous Leukemia: Results of a Randomized, Controlled StudyLeukemia & Lymphoma, 1993
- A randomized study of intermediate versus conventional‐dose cytarabine as intensive induction for acute myelogenous leukaemiaBritish Journal of Haematology, 1992
- A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing RiskThe Annals of Statistics, 1988